| |
| |
|
| Insider
Information: |
Healy James |
| Relationship: |
Director |
| City: |
Brisbane |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
17 |
|
| Direct
Shares |
4,066,962 |
|
|
Indirect Shares
|
23,168,630 |
|
|
| Direct
Value |
$5,104,641 |
|
|
|
Indirect Value
|
$274,085,407 |
|
|
| Total
Shares |
27,235,592 |
|
|
| Total
Value |
$279,190,048 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
4
|
5
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
4
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
-4.0
|
-4.0
|
| Percentage
Gain/Loss : |
 -46.5%
|
-63.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
InterMune Inc |
ITMN |
Director |
2014-09-29 |
0 |
2005-11-14 |
0 |
Premium* |
|
|
Anthera Pharmaceuticals Inc |
ANTH |
Director |
2012-01-28 |
32,443 |
2011-12-30 |
44,969 |
Premium* |
|
|
Amarin Corp Plc |
AMRN |
Director |
2012-08-31 |
90,000 |
2012-08-31 |
6,321,588 |
Premium* |
|
|
Humanigen Inc |
HGEN |
Director |
2013-02-05 |
0 |
2013-02-05 |
414,394 |
Premium* |
|
|
Ocera Therapeutics Inc |
OCRX |
10% Owner |
2014-03-18 |
9,364 |
2013-07-15 |
0 |
Premium* |
|
|
Hyperion Therapeutics Inc |
HPTX |
Director, 10% Owner |
2015-05-07 |
0 |
2015-05-07 |
0 |
Premium* |
|
|
Coherus Biosciences, Inc. |
CHRS |
Director |
2021-09-29 |
70,086 |
2021-09-29 |
0 |
Premium* |
|
|
Natera, Inc. |
NTRA |
|
2024-04-26 |
42,710 |
2024-04-26 |
1,550,280 |
Premium* |
|
|
PDS Biotechnology Corp |
PDSB |
Director |
2015-10-06 |
0 |
2016-03-11 |
2,852,711 |
Premium* |
|
|
Iterum Therapeutics Plc |
ITRM |
Director, 10% Owner |
2019-05-24 |
6,154 |
2019-05-24 |
1,726,514 |
Premium* |
|
|
Y-Mabs Therapeutics Inc |
YMAB |
Director |
2023-06-08 |
28,108 |
2023-06-08 |
2,194,278 |
Premium* |
|
|
Karuna Therapeutics, Inc. |
KRTX |
|
2024-03-18 |
0 |
2024-03-18 |
0 |
Premium* |
|
|
Checkmate Pharmaceuticals, Inc. |
CMPI |
10% Owner |
2020-08-11 |
0 |
2020-08-11 |
3,606,707 |
Premium* |
|
|
Bolt Biotherapeutics, Inc. |
BOLT |
Director |
2021-02-09 |
0 |
2021-02-09 |
2,754,437 |
Premium* |
|
|
Aerovate Therapeutics, Inc. |
AVTE |
10% Owner |
2021-07-02 |
3,758,686 |
2021-07-02 |
0 |
Premium* |
|
|
Cincor Pharma, Inc. |
CINC |
Director, 10% Owner |
2022-08-11 |
29,411 |
2022-08-11 |
6,000 |
Premium* |
|
|
Arrivent Biopharma, Inc. |
AVBP |
Director |
2024-01-30 |
0 |
2024-01-30 |
1,696,752 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
112 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ITMN |
InterMune Inc |
Director |
– • – |
2005-11-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
75,132 |
|
- |
|
| ITMN |
InterMune Inc |
Director |
– • – |
2010-12-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,499 |
4,150 |
0 |
- |
|
| HPTX |
Hyperion Therapeutics Inc |
Director |
– • • |
2015-05-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
6,849 |
5,006 |
0 |
- |
|
| ANTH |
Anthera Pharmaceuticals I... |
Director |
– • – |
2010-02-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,443 |
|
- |
|
| OCRX |
Ocera Therapeutics Inc |
10% Owner |
– – • |
2013-07-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
851,326 |
|
- |
|
| CHRS |
Coherus Biosciences, Inc. |
Director |
– • – |
2014-11-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
134,973 |
|
- |
|
| ITMN |
InterMune Inc |
Director |
– • – |
2010-01-26 |
4 |
OE |
$4.50 |
$22,500 |
D/D |
5,000 |
6,649 |
0 |
- |
|
| ANTH |
Anthera Pharmaceuticals I... |
Director |
– • – |
2012-01-28 |
4 |
OE |
$4.19 |
$50,280 |
D/D |
12,000 |
32,443 |
0 |
- |
|
| AMRN |
Amarin Corp Plc |
Director |
– • – |
2012-08-14 |
4 |
OE |
$1.50 |
$1,212,300 |
I/I |
808,200 |
6,321,588 |
0 |
- |
|
| AMRN |
Amarin Corp Plc |
Director |
– • – |
2012-08-31 |
4 |
OE |
$1.03 |
$30,900 |
D/D |
30,000 |
90,000 |
0 |
- |
|
| ITMN |
InterMune Inc |
Director |
– • – |
2014-05-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
13,549 |
0 |
- |
|
| NTRA |
Natera, Inc. |
Director |
– • – |
2019-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,278 |
7,278 |
0 |
- |
|
| ITRM |
Iterum Therapeutics Plc |
Director |
– • • |
2019-05-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,154 |
6,154 |
0 |
- |
|
| CHRS |
Coherus Biosciences, Inc. |
Director |
– • – |
2020-01-09 |
4 |
OE |
$1.67 |
$251,000 |
D/D |
49,994 |
50,086 |
0 |
- |
|
| NTRA |
Natera, Inc. |
Director |
– • – |
2020-01-10 |
4 |
OE |
$10.41 |
$248,063 |
D/D |
22,338 |
29,616 |
0 |
- |
|
| CHRS |
Coherus Biosciences, Inc. |
Director |
– • – |
2020-01-12 |
4 |
OE |
$12.37 |
$247,400 |
D/D |
20,000 |
70,086 |
0 |
- |
|
| YMAB |
Y-Mabs Therapeutics Inc |
Director |
– • – |
2020-01-15 |
4 |
OE |
$11.16 |
$370,002 |
D/D |
25,778 |
25,778 |
0 |
- |
|
| NTRA |
Natera, Inc. |
|
– • – |
2021-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,856 |
32,472 |
0 |
- |
|
| NTRA |
Natera, Inc. |
|
– • – |
2022-05-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,307 |
33,779 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
|
– • – |
2022-08-05 |
4 |
OE |
$16.00 |
$520,000 |
D/D |
32,500 |
32,500 |
0 |
- |
|
| CINC |
Cincor Pharma, Inc. |
Director |
– • • |
2022-08-05 |
4 |
OE |
$13.60 |
$399,990 |
D/D |
29,411 |
29,411 |
0 |
- |
|
| NTRA |
Natera, Inc. |
|
– • – |
2023-05-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,534 |
38,762 |
0 |
- |
|
| ITMN |
InterMune Inc |
Director |
– • – |
2006-02-22 |
4 |
S |
$18.80 |
$188,000 |
D/D |
(10,000) |
29,190 |
|
- |
|
| ITMN |
InterMune Inc |
Director |
– • – |
2006-02-23 |
4 |
S |
$19.05 |
$95,250 |
D/D |
(5,000) |
24,190 |
|
- |
|
| ITMN |
InterMune Inc |
Director |
– • – |
2006-02-24 |
4 |
S |
$19.10 |
$95,500 |
D/D |
(5,000) |
19,190 |
0 |
- |
|
112 Records found
|
|
Page 4 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
